Research Archive — Page 176 of 194

Microscopic tissue section stained in pink and purple, showing densely packed abnormal-looking cells surrounding irregular white spaces with numerous red blood cells.
September 27, 2012

Target acquired for aggressive tumor

New therapeutic target for angiosarcoma – an aggressive, highly fatal tumor of the blood vessels – identified.

Illustration of a translucent blue cell with a purple nucleus surrounded by colorful, spiky virus-like particles and bubbles.
September 25, 2012

Cell entry ports for cold virus

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.

puzzel pieces, autism
September 24, 2012

Little evidence supports medical treatment options for adolescents with autism

Despite studies that show that many adolescents and young adults with autism spectrum disorders are being prescribed medications, there is almost no evidence to show whether these medications are helpful in this population.

A bearded man in a striped shirt and red tie smiles in a research laboratory while a woman in a white lab coat works at a microscope and computer behind him.
September 21, 2012

VU, Bristol-Myers to collaborate on Parkinson’s therapies

Vanderbilt University and Bristol-Myers Squibb have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators, or PAMs, for the treatment of Parkinson’s disease.

Illustration of the human respiratory system showing the lungs, bronchi, and rib cage in glowing purple, orange, and yellow tones.
September 21, 2012

HER2 may impact lung cancer therapy

A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies.

September 20, 2012

Grant renewal boosts GI cancer research program

Vanderbilt-Ingram Cancer Center’s gastrointestinal Specialized Program of Research Excellence (SPORE) has been awarded its third round of funding by the National Cancer Institute (NCI).